Eli Lilly and Company $LLY Shares Sold by Bank Hapoalim BM

Bank Hapoalim BM lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 4.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,071 shares of the company’s stock after selling 143 shares during the period. Bank Hapoalim BM’s holdings in Eli Lilly and Company were worth $2,394,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. LGT Fund Management Co Ltd. increased its position in shares of Eli Lilly and Company by 20.1% in the second quarter. LGT Fund Management Co Ltd. now owns 34,117 shares of the company’s stock worth $26,595,000 after acquiring an additional 5,710 shares in the last quarter. Future Financial Wealth Managment LLC increased its position in shares of Eli Lilly and Company by 7.6% in the second quarter. Future Financial Wealth Managment LLC now owns 1,698 shares of the company’s stock worth $1,324,000 after acquiring an additional 120 shares in the last quarter. Ameriflex Group Inc. increased its position in shares of Eli Lilly and Company by 4.7% in the second quarter. Ameriflex Group Inc. now owns 1,170 shares of the company’s stock worth $930,000 after acquiring an additional 52 shares in the last quarter. QRG Capital Management Inc. increased its position in shares of Eli Lilly and Company by 2.5% in the second quarter. QRG Capital Management Inc. now owns 129,427 shares of the company’s stock worth $100,892,000 after acquiring an additional 3,202 shares in the last quarter. Finally, Successful Portfolios LLC increased its position in shares of Eli Lilly and Company by 2.5% in the second quarter. Successful Portfolios LLC now owns 1,301 shares of the company’s stock worth $1,014,000 after acquiring an additional 32 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 2.5%

NYSE LLY opened at $840.46 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market capitalization of $795.47 billion, a price-to-earnings ratio of 54.93, a price-to-earnings-growth ratio of 1.14 and a beta of 0.47. The company’s fifty day moving average price is $734.60 and its two-hundred day moving average price is $766.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the firm posted $3.92 EPS. The firm’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock worth $2,894,841 over the last ninety days. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent research reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Saturday, September 27th. Morgan Stanley decreased their target price on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research note on Friday. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Cantor Fitzgerald decreased their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research note on Wednesday, August 13th. Finally, DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $933.39.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.